This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Quest Diagnostics Names Jim Davis, Senior Vice President, Diagnostic Solutions

Stocks in this article: DGX

MADISON, N.J., April 16, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, announced today that Jim Davis, a former vice president for three GE healthcare businesses, has joined Quest Diagnostics as Senior Vice President, Diagnostic Solutions.

In this role, Mr. Davis will lead the company's Diagnostic Solutions business. In this role, he will oversee Diagnostic Products, Insurer Services, Clinical Trials and Healthcare Information Technology. Mr. Davis also will lead the company's Employer Solutions business. He reports to Steve Rusckowski, president and CEO.

Mr. Davis will succeed Kathy Ordonez, who will work with Mr. Davis to ensure a smooth leadership transition before leaving the company.

"Jim brings tremendous experience at growing and restructuring complex healthcare businesses, including in diagnostics and healthcare information technology," said Mr. Rusckowski. "I want to thank Kathy for her leadership and many contributions, including her dedicated work in bringing Celera and Berkeley HeartLab into our portfolio. We wish her well in the days ahead."

Most recently, Mr. Davis served as CEO of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by Magnetic Resonance Imaging (MRI) systems. Prior to that, he held vice president and general manager roles at GE's MRI, diagnostics imaging and healthcare information technology businesses, where he established a record for achieving growth and operational improvement. Prior to GE, Mr. Davis led the development of strategic and operating initiatives for clients of McKinsey.

Mr. Davis holds a business management degree from the Massachusetts Institute of Technology's Sloan School of Management, a master's of science degree in applied mathematics and operations research from MIT, and a bachelor's of science degree in in aeronautical engineering from the University of Michigan.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX .

Quest Diagnostics Contacts:  Wendy Bost (Media): 973-520-2800  Dan Haemmerle (Investors): 973-520-2900

SOURCE Quest Diagnostics Incorporated

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs